1. Altar CA, Boyer WC, Wasley A, Liebman JM, Wood PL, Gerhardt SG (1988) Dopamine neurochemical profile of atypical antipsychotics resemble that of D-1 antagonists. Naunyn-Schmiedeberg's Arch Pharmacol 338:162–168
2. Anderson PH, Braestrup C (1986) Evidence for different affinity states of the dopamine D-1 receptor: clozapine and fluperlapine may preferentially label an adenylate cyclase-coupled state of the D-1 receptor. J Neurochem 47:1830–1831
3. Ashgari V, Schoots O, VanKats S, Ohano K, Jovanovic V, Guan HC, Bunzow BR, Petronis A, Van Tol HH (1994) Dopamine D4 receptor repeat: analysis of distinct native and mutant forms of the human and rat genes. Mol Pharmacol 46:364–373
4. Beasley CM, Tolefson G, Tran P, Satterlee W, Sanger T, Hamilton S and the Olanzapine HGAD Study Group (1995) Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology (in press)
5. Bolden C, Cusack B, Richelson E (1992) Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in chinese hamster ovary cells. J Pharmacol Exp Ther 260:576–580